

Supplementary information to:

The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis

Supplementary Materials

Table of Contents

Supplementary method 1. Searching strategy for prevalence and burden of hepatitis E virus (HEV) infection in the global population. (page 4-5)

Figure S1. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on different countries. (page 6-11)

Figure S2. Forest plot of estimated pooled anti-HEV IgM seroprevalence among general population based on different countries. (page 12-14)

Figure S3. Forest plot of estimated pooled HEV RNA positive rate among general population based on different countries. (page 15-16)

Figure S4. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on different continents. (page 17-20)

Figure S5. Forest plot of estimated pooled anti-HEV IgM seroprevalence among general population based on different continents. (page 21-22)

Figure S6. Forest plot of estimated pooled HEV RNA positive rate among general population based on different continents. (page 23)

Figure S7. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on different ages. (page 24-28)

Figure S8. Anti-HEV IgG seroprevalence among different age range for general population from different continents. (page 29)

Figure S9. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on different genders. (page 30-33)

Figure S10. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on high income countries, upper-middle income countries, lower middle income countries, and low income countries. (page 34-37)

Figure S11. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on developed countries and developing countries. (page 38-41)

Figure S12. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on time period of 1993-2006 and 2007-2019. (page 42-45)

Figure S13. Forest plot of estimated pooled anti-HEV IgG seroprevalence among swine-related occupational population based on different countries. (page 46-47)

Figure S14. Forest plot of estimated pooled anti-HEV IgG seroprevalence among special population. (page 48-49)

Figure S15. Forest plot of estimated pooled anti-HEV IgM seroprevalence among special population. (page 50)

Figure S16. Forest plot of estimated pooled HEV RNA positive rate among special population. (page 51)

Figure S17. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among hepatitis population. (page 52)

Figure S18. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among hepatitis population. (page 53)

Figure S19. Forest plot of estimated pooled HEV RNA positive rate among hepatitis population. (page 54)

Figure S20. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among HIV population based on different countries. (page 55-57)

Figure S21. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among HIV population based on different countries. (page 58-59)

Figure S22. Forest plot of estimated pooled HEV RNA positive rate among HIV population based on different countries. (page 60)

Figure S23. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among transplant population based on different countries. (page 61)

Figure S24. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among transplant population based on different countries. (page 62)

Figure S25. Forest plot of estimated pooled HEV RNA positive rate among transplant population based on different countries. (page 63)

Figure S26. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among hemodialysis population based on different countries. (page 64)

Figure S27. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among hemodialysis population based on different countries. (page 65)

Figure S28. Pooled Odd Ratios of anti-HEV IgG seroprevalence to investigate the risk factors for HEV infection among general population. (page 66)

Figure S29. Odds ratio analysis of anti-HEV IgG seroprevalence for people contacting dogs or not in general population. (page 67)

Figure S30. Odds ratio analysis of anti-HEV IgG seroprevalence for people contacting cats or not in general population. (page 67)

Figure S31. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without blood transfusion in general population. (page 67)

Figure S32. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without consumption of raw meat in general population. (page 68)

Figure S33. Odds ratio analysis of anti-HEV IgG seroprevalence for people frequently exposed to soil or unexposed to soil in general population. (page 68)

Figure S34. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without travelling to endemic areas in general population. (page 68)

Figure S35. Odds ratio analysis of anti-HEV IgG seroprevalence for urban residents or rural residents in general population. (page 69)

Figure S36. Odds ratio analysis of anti-HEV IgG seroprevalence for people receive water source of tap/well/river in general population. (page 70)

Figure S37. Odds ratio analysis of anti-HEV IgG seroprevalence for people accepting education of elementary or above elementary in general population. (page 71)

Figure S38. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without MSM experience in general population. (page 72)

Figure S39. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without IDU experience in general population. (page 72)

Figure S40. Forest plot of estimated pooled anti-HEV IgG positive rate among general population based on different ELISA manufactures. (page 73-76)

Figure S41. Funnel plot for anti-HEV IgG seroprevalence among general population. (page 77)

Figure S42. Egger plot for anti-HEV IgG seroprevalence among general population. (page 77)

Table S1. Score of studies evaluated by JBI Critical Appraisal Tools. (page 78-88)

Table S2. Distribution of HEV genotypes 1-4 in different countries. (page 89-90)

Table S3. Sensitivity analysis in epidemiology of anti-HEV IgG in general population. (page 91-94)

Table S4. Manufactures of ELISA assays used in general population. (page 95-98)

Table S5. HEV prevalence among occupational population and special population. (page 99)

Supplementary file 1.

We systematically searched Embase.com, Medline Ovid, Web of science, Cochrane CENTRAL, Google scholar to identify studies providing prevalence rate of HEV.

Embase.com	3196	3123
Medline Ovid	2786	592
Web of science	1885	453
Cochrane CENTRAL	28	9
Google scholar	200	36
Total	8095	4213

The search terms used in different database were as follows:

Embase.com

('Hepatitis E virus'/de OR 'hepatitis E'/de OR 'hepatitis E antibody'/de OR 'hepatitis E antigen'/de OR ((Hepatitis NEAR/3 E) OR hev):ab,ti) AND ('epidemiological data'/de OR 'epidemiology'/de OR 'geographic distribution'/de OR incidence/exp OR 'patient volume'/de OR prevalence/exp OR 'infection rate'/de OR 'age distribution'/de OR seroepidemiology/de OR 'occupation'/de OR vocation/de OR specialization/de OR 'virus virulence'/de OR virulence/de OR geography/de OR 'occupational disease'/de OR 'occupational exposure'/de OR 'occupational health'/de OR 'occupational hazard'/de OR 'geographic names'/exp OR (epidemiolog* OR seroepidemiolog* OR ((geograph* OR global* OR age) NEAR/3 (distribut*)) OR incidenc* OR (patient* NEAR/3 volume*) OR prevalen* OR seroprevalen* OR (infection* NEAR/3 rate*) OR occupation* OR vocation* OR virulen* OR specialization* OR specialisation*):ab,ti) NOT (hepatitis-b-e NOT hepatitis-e) NOT ([animals]/lim NOT [humans]/lim) NOT ('case report'/de OR 'case report*':ti) NOT ([Conference Abstract]/lim) AND [english]/lim

Medline Ovid

(Hepatitis E virus/ OR Hepatitis E/ OR ((Hepatitis ADJ3 E) OR hev).ab,ti.) AND (Epidemiological Monitoring/ OR Epidemiology/ OR Epidemiology.fs. OR exp Incidence/ OR exp Prevalence/ OR Age Distribution/ OR Occupations/ OR Specialization/ OR Virulence/ OR Geography/ OR Occupational Diseases/ OR Occupational Exposure/ OR Occupational Health/ OR exp Geographic Locations/ OR (epidemiolog* OR seroepidemiolog* OR ((geograph* OR global* OR age) ADJ3 (distribut*)) OR incidenc* OR (patient* ADJ3 volume*) OR prevalen* OR seroprevalen* OR (infection* ADJ3 rate*) OR occupation* OR vocation* OR virulen* OR specialization* OR specialisation*).ab,ti.) NOT (hepatitis-b-e NOT hepatitis-e) NOT (exp animals/ NOT humans/) NOT (case report/ OR case report*.ti.) AND english.la.

Web of science

TS=(((Hepatitis NEAR/2 E) OR hev)) AND ((epidemiolog* OR seroepidemiolog* OR ((geograph* OR global* OR age) NEAR/2 (distribut*)) OR incidenc* OR (patient* NEAR/2 volume*) OR prevalen* OR seroprevalen* OR (infection* NEAR/2 rate*) OR occupation* OR vocation* OR virulen* ORspecialization* OR specialisation*)) NOT (hepatitis-b-e NOT hepatitis-e) NOT ((animal* OR rat OR rats OR mouse OR mice OR murine OR dog OR dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR cows OR bovine OR rodent* OR sheep OR ovine OR pig OR swine OR porcine OR veterinar* OR chick* OR zebrafish* OR baboon* OR nonhuman* OR primate* OR cattle* OR goose OR geese OR duck OR macaque* OR avian* OR bird* OR fish*) NOT (human* OR patient* OR women OR woman OR men OR man))) AND DT=(article) AND LA=(english) NOT TI=("case report*")

Cochrane CENTRAL

((Hepatitis NEAR/3 E) OR hev):ab,ti) AND ((epidemiolog* OR seroepidemiolog* OR ((geograph* OR global* OR age) NEAR/3 (distribut*)) OR incidenc* OR (patient* NEAR/3 volume*) OR prevalen* OR seroprevalen* OR (infection* NEAR/3 rate*) OR occupation* OR vocation* OR virulen* OR specialization* OR specialisation*):ab,ti) NOT (hepatitis next b next e NOT hepatitis next e)

Google scholar

"HepatitisE" epidemiology|seroepidemiology|"geographic|global|age distribution"|incidence|"patient volume"|prevalence|seroprevalence|"infection rate"|occupational|virulence

Study selection criteria

Study population:

General population: blood donors, pregnant women, healthy people, hospital attendants

Occupational population: veterinarians, swine workers, slaughterhouse workers, pork sellers


Special population: people suffering hemodialysis, people with acute hepatitis (hepatitis caused by hepatitis B virus or hepatitis C virus or unknown pathogen), HIV-infected population, transplant recipients (renal transplant, liver transplant, lung transplant, heart transplant, bone marrow transplant).


Study inclusion criteria: provide data related to prevalence of hepatitis E virus infection.


Study exclusion criteria: case reports, reviews, none-HEV studies, antiviral research of HEV, study of clinical drug effect, no primary data, outbreak, animal HEV studies, replicate data in same areas, study population below 50 for general population, study population below 50 for occupational and special population.

Figure S1. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on different countries.

Note: country named multiple means people in the study are from more than one country. For example, Halliday et al, 2014 contained people from Papua New Guinea, Fiji, Kiribati; Baylis yet al, 2012 contained people from Sweden, Germany and USA.







Country = Ireland			
O'Riordan et al, 2016	57	1076	0.0530 [0.0404; 0.0681] 0.3%
Hickey et al, 2016	16	198	0.0808 [0.0469; 0.1279] 0.3%
Random effects model		1274	0.0617 [0.0392; 0.0890] 0.7%
Heterogeneity: $I^2 = 52\%$, $\tau^2 = 0.0008$, $p = 0.15$			
Country = Israel			
Mor et al, 2015	77	729	0.1056 [0.0843; 0.1302] 0.3%
Karetny et al, 1995	37	1416	0.0261 [0.0185; 0.0358] 0.4%
Lachish et al, 2013	19	4970	0.0038 [0.0023; 0.0060] 0.4%
Random effects model		7115	0.0336 [0.0019; 0.1022] 1.1%
Heterogeneity: $I^2 = 99\%$, $\tau^2 = 0.0154$, $p < 0.01$			
Country = Italy			
Spada et al, 2018	869	10011	0.0868 [0.0814; 0.0925] 0.4%
Gessoni et al, 1996	49	1889	0.0259 [0.0193; 0.0341] 0.4%
Ricco et al, 2016	9	199	0.0452 [0.0209; 0.0841] 0.3%
Puttini et al, 2015	12	132	0.0909 [0.0479; 0.1534] 0.3%
Pavia et al, 1998	3	360	0.0083 [0.0017; 0.0242] 0.3%
Zuin et al, 2016	380	3546	0.1072 [0.0972; 0.1178] 0.4%
Scotto et al, 2012	2	151	0.0132 [0.0016; 0.0470] 0.3%
Sabato et al, 2017	4	253	0.0158 [0.0043; 0.0400] 0.3%
Lucarelli et al, 2016	153	313	0.4888 [0.4322; 0.5457] 0.3%
Marcantonio et al, 2018	10	198	0.0505 [0.0245; 0.0909] 0.3%
Lanini et al, 2015	60	1116	0.0538 [0.0413; 0.0687] 0.4%
Rapicetta et al, 1999	113	973	0.1161 [0.0967; 0.1380] 0.3%
Tabili et al, 2013	23	103	0.2233 [0.1471; 0.3160] 0.3%
Alecci et al, 1997	3	244	0.0123 [0.0025; 0.0355] 0.3%
Random effects model		19488	0.0728 [0.0454; 0.1060] 4.9%
Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0116$, $p < 0.01$			
Country = Japan			
Takahashi et al, 2010	1167	22027	0.0530 [0.0501; 0.0560] 0.4%
Takeda et al, 2010	431	12600	0.0342 [0.0311; 0.0375] 0.4%
Sakata et al, 2008	45	1389	0.0324 [0.0237; 0.0431] 0.4%
Toyoda et al, 2008	60	592	0.1014 [0.0782; 0.1285] 0.3%
Fukuda et al, 2007	168	3185	0.0527 [0.0452; 0.0611] 0.4%
Ding et al, 2003	15	533	0.0281 [0.0158; 0.0460] 0.3%
Mitsui et al, 2005	6	266	0.0226 [0.0083; 0.0484] 0.3%
Goto et al, 2006	9	344	0.0262 [0.0120; 0.0491] 0.3%
Random effects model		40936	0.0426 [0.0327; 0.0537] 2.8%
Heterogeneity: $I^2 = 94\%$, $\tau^2 = 0.0011$, $p < 0.01$			
Country = Jordan			
Mohammad et al, 2017	139	450	0.3089 [0.2665; 0.3538] 0.3%
Random effects model		450	0.3089 [0.2671; 0.3523] 0.3%
Heterogeneity: not applicable			
Country = Kazakhstan			
Cainelli et al, 2018	11	199	0.0553 [0.0279; 0.0968] 0.3%
Random effects model		199	0.0553 [0.0279; 0.0912] 0.3%
Heterogeneity: not applicable			
Country = Korea			
Ahn et al, 2005	138	1030	0.1340 [0.1138; 0.1563] 0.3%
Yoon et al, 2014	144	2450	0.0588 [0.0498; 0.0688] 0.4%
Yun et al, 2011	46	489	0.0941 [0.0697; 0.1235] 0.3%
Random effects model		3969	0.0930 [0.0487; 0.1496] 1.0%
Heterogeneity: $I^2 = 96\%$, $\tau^2 = 0.0057$, $p < 0.01$			
Country = Laos			
Khounvisith et al, 2018	38	210	0.1810 [0.1313; 0.2398] 0.3%
Random effects model		210	0.1810 [0.1320; 0.2358] 0.3%
Heterogeneity: not applicable			
Country = Malawi			
Taha et al, 2015	80	397	0.2015 [0.1631; 0.2444] 0.3%
Random effects model		397	0.2015 [0.1636; 0.2423] 0.3%
Heterogeneity: not applicable			
Country = Mexico			
Esquivel et al, 2014	100	273	0.3663 [0.3090; 0.4265] 0.3%
Munoz et al, 1999	374	3549	0.1054 [0.0955; 0.1160] 0.4%
Héctor et al, 2017	1	127	0.0079 [0.0002; 0.0431] 0.3%
Cosme et al, 2014	25	439	0.0569 [0.0372; 0.0829] 0.3%
Esquivel et al, 2015	10	150	0.0667 [0.0324; 0.1192] 0.3%
Esquivel et al, 2015	25	439	0.0569 [0.0372; 0.0829] 0.3%
Random effects model		4977	0.0897 [0.0375; 0.1614] 2.1%
Heterogeneity: $I^2 = 97\%$, $\tau^2 = 0.0177$, $p < 0.01$			
Country = Moldova			
Drobeniuc et al, 2001	63	255	0.2471 [0.1954; 0.3047] 0.3%
Random effects model		255	0.2471 [0.1962; 0.3018] 0.3%
Heterogeneity: not applicable			
Country = Mongolia			
Takahashi et al, 2004	28	249	0.1124 [0.0760; 0.1584] 0.3%
Davaalkham et al, 2009	3	520	0.0058 [0.0012; 0.0168] 0.3%
Bira et al, 2007	5	717	0.0070 [0.0023; 0.0162] 0.3%
Random effects model		1486	0.0270 [0.0006; 0.0908] 1.0%
Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0149$, $p < 0.01$			








Figure S2. Forest plot of estimated pooled anti-HEV IgM seroprevalence among general population based on different countries.

Note: country named multiple means people in the study are from more than one country.








Figure S3. Forest plot of estimated pooled HEV RNA positive rate among general population based on different countries.

Note: country named multiple means people in the study are from more than one country.








Figure S4. Forest plot of estimated anti-HEV IgG seroprevalence among general population based on different continents.

Note: continent named multiple means people in the study are from more than one country and cannot be included into one continent.





Continent = Europe

Maria et al, 2006	96	1280		0.0750 [0.0612; 0.0908]	0.4%
Boutrouille et al, 2007	64	1998		0.0320 [0.0248; 0.0407]	0.4%
Christensen et al, 2018	293	906		0.3234 [0.2930; 0.3549]	0.3%
O'Riordan et al, 2016	57	1076		0.0530 [0.0404; 0.0681]	0.3%
Spada et al, 2018	869	10011		0.0868 [0.0814; 0.0925]	0.4%
Nascimento et al, 2016	270	1656		0.1630 [0.1456; 0.1817]	0.4%
Verhoef et al, 2011	134	7072		0.0189 [0.0159; 0.0224]	0.4%
Mooij et al, 2018	648	2100		0.3086 [0.2889; 0.3288]	0.4%
Lafeber et al, 2017	666	2422		0.2750 [0.2573; 0.2932]	0.4%
Olcay et al, 2003	57	910		0.0626 [0.0478; 0.0804]	0.3%
Rapicetta et al, 1999	33	2233		0.0148 [0.0102; 0.0207]	0.4%
Slot et al, 2013	1401	5239		0.2674 [0.2555; 0.2796]	0.4%
Straková et al, 2016	13	230		0.0565 [0.0304; 0.0947]	0.3%
Wenzel et al, 2014	929	2184		0.4254 [0.4045; 0.4464]	0.4%
Petrovi et al, 2014	30	200		0.1500 [0.1035; 0.2072]	0.3%
Sadik et al, 2016	459	1199		0.3828 [0.3552; 0.4110]	0.4%
Thom et al, 2017	104	2311		0.0450 [0.0369; 0.0543]	0.4%
Sauleda et al, 2014	1996	9998		0.1996 [0.1918; 0.2076]	0.4%
Pittaras et al, 2014	25	265		0.0943 [0.0620; 0.1361]	0.3%
Niederhauser et al, 2017	737	3609		0.2042 [0.1912; 0.2177]	0.4%
Teoharov et al, 2014	67	741		0.0904 [0.0708; 0.1134]	0.3%
Alberts et al, 2018	190	7065		0.0269 [0.0232; 0.0309]	0.4%
Grabarczyk et al, 2018	1340	3079		0.4352 [0.4176; 0.4529]	0.4%
Gessoni et al, 1996	49	1889		0.0259 [0.0193; 0.0341]	0.4%
Fogeda et al, 2012	25	2305		0.0108 [0.0070; 0.0160]	0.4%
Fischer et al, 2014	163	1203		0.1355 [0.1166; 0.1561]	0.4%
Harvala et al, 2018	42	480		0.0875 [0.0638; 0.1164]	0.3%
Cleland et al, 2013	73	1559		0.0468 [0.0369; 0.0585]	0.4%
Dimiglio et al, 2018	23	300		0.0767 [0.0492; 0.1128]	0.3%
Anita et al, 2014	22	148		0.1486 [0.0956; 0.2164]	0.3%
Hogema et al, 2016	11	45		0.2444 [0.1288; 0.3954]	0.3%
Hickey et al, 2016	16	198		0.0808 [0.0469; 0.1279]	0.3%
Bernal et al, 1995	36	1757		0.0205 [0.0144; 0.0283]	0.4%
Ricco et al, 2016	9	199		0.0452 [0.0209; 0.0841]	0.3%
Puttini et al, 2015	12	132		0.0909 [0.0479; 0.1534]	0.3%
Pavia et al, 1998	3	360		0.0083 [0.0017; 0.0242]	0.3%
Zuin et al, 2016	380	3546		0.1072 [0.0972; 0.1178]	0.4%
Scotto et al, 2012	2	151		0.0132 [0.0016; 0.0470]	0.3%
Sabato et al, 2017	4	253		0.0158 [0.0043; 0.0400]	0.3%
Love et al, 2018	6	291		0.0206 [0.0076; 0.0443]	0.3%
Mansuy et al, 2016	2371	10569		0.2243 [0.2164; 0.2324]	0.4%
Karetny et al, 1995	37	1416		0.0261 [0.0185; 0.0358]	0.4%
Lucarelli et al, 2016	153	313		0.4888 [0.4322; 0.5457]	0.3%
Lange et al, 2016	177	1263		0.1401 [0.1215; 0.1605]	0.4%
Mateos et al, 1998	34	905		0.0376 [0.0262; 0.0521]	0.3%
Marcantonio et al, 2018	10	198		0.0505 [0.0245; 0.0909]	0.3%
Lanini et al, 2015	60	1116		0.0538 [0.0413; 0.0687]	0.4%
Kaufmann et al, 2011	27	550		0.0491 [0.0326; 0.0706]	0.3%
Mansuy et al, 2004	46	431		0.1067 [0.0792; 0.1398]	0.3%
Mansuy et al, 2015	1310	3353		0.3907 [0.3741; 0.4074]	0.4%
Juhl et al, 2017	70	449		0.1559 [0.1236; 0.1928]	0.3%
Juhl et al, 2014	69	1019		0.0677 [0.0531; 0.0849]	0.3%
Nagler et al, 2014	143	997		0.1434 [0.1222; 0.1667]	0.3%
Langer et al, 1997	3	553		0.0054 [0.0011; 0.0158]	0.3%
Lavanchy et al, 1994	14	317		0.0442 [0.0244; 0.0730]	0.3%
Mahrt et al, 2018	679	3000		0.2263 [0.2115; 0.2417]	0.4%
Krumbholz et al, 2011	18	116		0.1552 [0.0946; 0.2341]	0.3%
Krumbholz et al, 2014	65	537		0.1210 [0.0947; 0.1517]	0.3%
Jeggli et al, 2015	25	752		0.0332 [0.0216; 0.0487]	0.3%
Kantala et al, 2015	37	385		0.0961 [0.0686; 0.1300]	0.3%
Korzeniewski et al, 2018	13	253		0.0514 [0.0276; 0.0863]	0.3%
Jablonka et al, 2017	122	604		0.2020 [0.1707; 0.2363]	0.3%
Kaba et al, 2010	57	490		0.1163 [0.0893; 0.1481]	0.3%
Chironna et al, 1999	20	526		0.0380 [0.0234; 0.0581]	0.3%
Rapicetta et al, 1999	113	973		0.1161 [0.0967; 0.1380]	0.3%
Schielke et al, 2015	26	126		0.2063 [0.1394; 0.2875]	0.3%
Nöbling et al, 2002	20	511		0.0391 [0.0241; 0.0598]	0.3%
Todys et al, 2015	206	1027		0.2006 [0.1765; 0.2264]	0.3%
Meader et al, 2008	10	413		0.0242 [0.0117; 0.0441]	0.3%
Tabili et al, 2013	23	103		0.2233 [0.1471; 0.3160]	0.3%
Bura et al, 2018	2	138		0.0145 [0.0018; 0.0514]	0.3%
Dremsek et al, 2012	132	853		0.1547 [0.1311; 0.1808]	0.3%
Alecci et al, 1997	3	244		0.0123 [0.0025; 0.0355]	0.3%
Chaussade et al, 2013	83	322		0.2578 [0.2109; 0.3092]	0.3%
Teixeira et al, 2017	106	804		0.1318 [0.1092; 0.1572]	0.3%





Figure S5. Forest plot of estimated pooled anti-HEV IgM seroprevalence among general population based on different continents.

Note: continent named multiple means people in the study are from more than one country and cannot be included into one continent.






Figure S6. Forest plot of estimated pooled HEV RNA positive rate among general population based on different continents.

Note: continent named multiple means people in the study are from more than one country and cannot be included into one continent.







Figure S7. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population with different ages.




Age = 20-29



Age = 30-39



Age = 40-49






Figure S8. Anti-HEV IgG seroprevalence among different age range for general population from different continents






Figure S9. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population with different genders.



Arif et al, 1994	55	663		0.0830	[0.0631; 0.1066]	0.4%
Anita et al, 2014	4	40		0.1000	[0.0279; 0.2366]	0.4%
Grabow et al, 1994	1	98		0.0102	[0.0003; 0.0555]	0.4%
Hardtke et al, 2018	91	408		0.2230	[0.1836; 0.2666]	0.4%
Ataei et al, 2007	18	428		0.0421	[0.0251; 0.0657]	0.4%
Hesamizadeh et al, 2015	2	21		0.0952	[0.0117; 0.3038]	0.3%
Hickey et al, 2016	6	96		0.0625	[0.0233; 0.1311]	0.4%
Houcine et al, 2012	4	126		0.0317	[0.0087; 0.0793]	0.4%
Jahromi et al, 2013	1	30		0.0333	[0.0008; 0.1722]	0.3%
Adesina et al, 2009	16	141		0.1135	[0.0663; 0.1777]	0.4%
Bernal et al, 1995	26	993		0.0262	[0.0172; 0.0381]	0.4%
Pavia et al, 1998	1	77		0.0130	[0.0003; 0.0702]	0.4%
Raofi et al, 2012	17	226		0.0752	[0.0444; 0.1177]	0.4%
Rahman et al, 2014	42	150		0.2800	[0.2098; 0.3591]	0.4%
Chen et al, 2012	1179	5014		0.2351	[0.2235; 0.2471]	0.4%
Madden et al, 2016	163	620		0.2629	[0.2286; 0.2994]	0.4%
Mansuy et al, 2016	964	4946		0.1949	[0.1839; 0.2062]	0.4%
Karetny et al, 1995	8	361		0.0222	[0.0096; 0.0432]	0.4%
Lucarelli et al, 2016	24	61		0.3934	[0.2707; 0.5269]	0.4%
Lange et al, 2016	75	577		0.1300	[0.1036; 0.1602]	0.4%
Liang et al, 2014	49	124		0.3952	[0.3086; 0.4869]	0.4%
Marcantonio et al, 2018	2	45		0.0444	[0.0054; 0.1515]	0.4%
Lanini et al, 2015	18	414		0.0435	[0.0260; 0.0678]	0.4%
Jia et al, 2014	1751	7870		0.2225	[0.2133; 0.2318]	0.4%
Kaufmann et al, 2011	9	218		0.0413	[0.0190; 0.0769]	0.4%
Li et al, 2014	77	702		0.1097	[0.0875; 0.1352]	0.4%
Juhl et al, 2014	26	428		0.0607	[0.0401; 0.0877]	0.4%
Nagler et al, 2014	3	17		0.1765	[0.0380; 0.4343]	0.3%
Liu et al, 2019	2285	6903		0.3310	[0.3199; 0.3423]	0.4%
Mahrt et al, 2018	312	1500		0.2080	[0.1877; 0.2294]	0.4%
Kuniholm et al, 2009	2065	10124		0.2040	[0.1962; 0.2120]	0.4%
Krumbholz et al, 2011	21	90		0.2333	[0.1506; 0.3343]	0.4%
Jeggli et al, 2015	1	349		0.0029	[0.0001; 0.0159]	0.4%
Kang et al, 2017	227	411		0.5523	[0.5028; 0.6011]	0.4%
Matins et al, 2014	12	269		0.0446	[0.0233; 0.0766]	0.4%
Jahanbakhsh et al, 2017	124	484		0.2562	[0.2179; 0.2975]	0.4%
Rapicetta et al, 1999	14	126		0.1111	[0.0621; 0.1794]	0.4%
Esquivel et al, 2014	70	204		0.3431	[0.2783; 0.4127]	0.4%
Cui et al, 2016	111	521		0.2131	[0.1786; 0.2508]	0.4%
Schielke et al, 2015	2	8		0.2500	[0.0319; 0.6509]	0.2%
Meader et al, 2008	1	117		0.0085	[0.0002; 0.0467]	0.4%
Whiters et al, 2002	5	89		0.0562	[0.0185; 0.1263]	0.4%
Widasari et al, 2013	19	208		0.0913	[0.0559; 0.1390]	0.4%
Galiana et al, 2008	2	97		0.0206	[0.0025; 0.0725]	0.4%
Cheng et al, 2007	84	510		0.1647	[0.1336; 0.1998]	0.4%
Cong et al, 2014	98	476		0.2059	[0.1704; 0.2450]	0.4%
Bayhan et al, 2016	8	179		0.0447	[0.0195; 0.0862]	0.4%
Achwan et al, 2007	21	322		0.0652	[0.0408; 0.0980]	0.4%
Buti et al, 2008	35	607		0.0577	[0.0405; 0.0793]	0.4%
Davaalkham et al, 2009	1	223		0.0045	[0.0001; 0.0247]	0.4%
Ekanem et al, 2015	17	205		0.0829	[0.0491; 0.1295]	0.4%
Meng et al, 2015	103	784		0.1314	[0.1085; 0.1571]	0.4%









Figure S10. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on high income countries, upper-middle income countries, lower middle income countries, and low income countries.












Figure S11. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on developed countries and developing countries.

Note: subgroup named mixed means study contained people from several different countries and thus cannot be divided into developed country or developing country.





Nouhin et al, 2016	85	301		0.2824	[0.2322; 0.3369]	0.3%
Castilho et al, 2017	49	500		0.0980	[0.0734; 0.1275]	0.3%
Olcay et al, 2003	57	910		0.0626	[0.0478; 0.0804]	0.3%
Rapicetta et al, 1999	33	2233		0.0148	[0.0102; 0.0207]	0.4%
Nouhin et al, 2018	829	2004		0.4137	[0.3920; 0.4356]	0.4%
Wong et al, 2004	176	934		0.1884	[0.1638; 0.2150]	0.3%
Meldal et al, 2013	11	239		0.0460	[0.0232; 0.0809]	0.3%
Petrovi et al, 2014	30	200		0.1500	[0.1035; 0.2072]	0.3%
Wang et al, 2017	2682	9069		0.2957	[0.2864; 0.3052]	0.4%
Tripathy et al, 2018	433	2447		0.1770	[0.1620; 0.1927]	0.4%
Quintana et al, 2005	11	209		0.0526	[0.0266; 0.0922]	0.3%
Taremi et al, 2007	31	399		0.0777	[0.0534; 0.1085]	0.3%
Castilho et al, 2016	30	300		0.1000	[0.0685; 0.1397]	0.3%
Vivek et al, 2010	330	2279		0.1448	[0.1306; 0.1599]	0.4%
Zhu et al, 2008	1289	4654		0.2770	[0.2641; 0.2901]	0.4%
Mohebbi et al, 2012	51	551		0.0926	[0.0697; 0.1199]	0.3%
Yang et al, 2014	473	2028		0.2332	[0.2150; 0.2523]	0.4%
Zhu et al, 2014	152061	400162		0.3800	[0.3785; 0.3815]	0.4%
Villalba et al, 2014	47	469		0.1002	[0.0746; 0.1310]	0.3%
Shrestha et al, 2016	773	1845		0.4190	[0.3963; 0.4419]	0.4%
Mohammad et al, 2017	139	450		0.3089	[0.2665; 0.3538]	0.3%
Yamada et al, 2015	160	868		0.1843	[0.1591; 0.2118]	0.3%
Vitral et al, 2014	50	388		0.1289	[0.0972; 0.1663]	0.3%
Peng et al, 1995	76	997		0.0762	[0.0605; 0.0945]	0.3%
Talarmin et al, 1997	64	996		0.0643	[0.0498; 0.0813]	0.3%
Ren et al, 2013	2945	10741		0.2742	[0.2658; 0.2827]	0.4%
Santos et al, 2002	17	699		0.0243	[0.0142; 0.0387]	0.3%
Miller et al, 1998	1	403		0.0025	[0.0001; 0.0137]	0.3%
Parsa et al, 2016	50	700		0.0714	[0.0535; 0.0931]	0.3%
Schreuder et al, 2016	25	600		0.0417	[0.0271; 0.0609]	0.3%
Jahromi et al, 2013	26	477		0.0545	[0.0359; 0.0788]	0.3%
Teoharov et al, 2014	67	741		0.0904	[0.0708; 0.1134]	0.3%
Bortoliero et al, 2006	23	996		0.0231	[0.0147; 0.0344]	0.3%
Grabarczyk et al, 2018	1340	3079		0.4352	[0.4176; 0.4529]	0.4%
Feng et al, 2018	1273	1912		0.6658	[0.6441; 0.6869]	0.4%
Paula et al, 2001	10	255		0.0392	[0.0190; 0.0709]	0.3%
Goncales et al, 2000	18	357		0.0504	[0.0302; 0.0785]	0.3%
Cai et al, 2016	1842	3337		0.5520	[0.5349; 0.5690]	0.4%
Chiu et al, 2013	129	450		0.2867	[0.2453; 0.3309]	0.3%
Chan et al, 2017	492	1539		0.3197	[0.2964; 0.3436]	0.4%
Arif et al, 1994	160	1418		0.1128	[0.0968; 0.1305]	0.4%
Abdelaal et al, 1995	100	593		0.1686	[0.1394; 0.2012]	0.3%
Amarapurkar et al, 2008	416	1163		0.3577	[0.3301; 0.3860]	0.4%
Anita et al, 2014	22	148		0.1486	[0.0956; 0.2164]	0.3%
Grabow et al, 1994	16	782		0.0205	[0.0117; 0.0330]	0.3%
Hardtke et al, 2018	91	408		0.2230	[0.1836; 0.2666]	0.3%
Ataei et al, 2007	31	816		0.0380	[0.0260; 0.0535]	0.3%
Hesamizadeh et al, 2015	45	514		0.0875	[0.0646; 0.1154]	0.3%
Houcine et al, 2012	37	687		0.0539	[0.0382; 0.0735]	0.3%
Jahromi et al, 2013	26	477		0.0545	[0.0359; 0.0788]	0.3%
Sepanlou et al, 2010	105	1423		0.0738	[0.0607; 0.0886]	0.4%
Adesina et al, 2009	25	186		0.1344	[0.0889; 0.1920]	0.3%
Pujol et al, 1994	23	611		0.0376	[0.0240; 0.0559]	0.3%
Raofi et al, 2012	31	400		0.0775	[0.0533; 0.1082]	0.3%
Rahman et al, 2014	90	300		0.3000	[0.2487; 0.3553]	0.3%
Poororawan et al, 1996	61	1038		0.0588	[0.0452; 0.0749]	0.3%
Chen et al, 2012	2793	14208		0.1966	[0.1901; 0.2032]	0.4%
Madden et al, 2016	324	1161		0.2791	[0.2534; 0.3058]	0.4%
Lopes et al, 2017	78	300		0.2600	[0.2113; 0.3135]	0.3%
Kotwal et al, 2014	712	4175		0.1705	[0.1592; 0.1823]	0.4%
Liang et al, 2014	129	307		0.4202	[0.3644; 0.4776]	0.3%
Johargy et al, 2013	168	900		0.1867	[0.1617; 0.2137]	0.3%
Jia et al, 2014	3721	15862		0.2346	[0.2280; 0.2413]	0.4%
Ma et al, 2010	407	2090		0.1947	[0.1780; 0.2124]	0.4%
Li et al, 2011	69	173		0.3988	[0.3253; 0.4759]	0.3%
Konomi et al, 1999	93	574		0.1620	[0.1328; 0.1948]	0.3%
Li et al, 2014	197	1638		0.1203	[0.1049; 0.1370]	0.4%
Katiyar et al, 2018	383	633		0.6051	[0.5658; 0.6434]	0.3%
Intharasongkroh et al, 2019	0	1019		0.0000	[0.0000; 0.0036]	0.3%
Kamel et al, 1995	214	1259		0.1700	[0.1496; 0.1919]	0.4%
Lee et al, 1993	43	984		0.0437	[0.0318; 0.0584]	0.3%
Ibarra et al, 1994	82	469		0.1748	[0.1415; 0.2123]	0.3%
Liu et al, 2019	3419	10256		0.3334	[0.3242; 0.3426]	0.4%
Khounvisith et al, 2018	38	210		0.1810	[0.1313; 0.2398]	0.3%






Figure S12. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on time period of 1993-2006 and 2007-2019.





Parsa et al, 2016	50	700		0.0714	[0.0535; 0.0931]	0.3%
Pittaras et al, 2014	25	265		0.0943	[0.0620; 0.1361]	0.3%
Schreuder et al, 2016	25	600		0.0417	[0.0271; 0.0609]	0.3%
Jahromi et al, 2013	26	477		0.0545	[0.0359; 0.0788]	0.3%
Niederhauser et al, 2017	737	3609		0.2042	[0.1912; 0.2177]	0.4%
Teoharov et al, 2014	67	741		0.0904	[0.0708; 0.1134]	0.3%
Hewitt et al, 2018	98	1013		0.0967	[0.0792; 0.1166]	0.3%
Alberts et al, 2018	190	7065		0.0269	[0.0232; 0.0309]	0.4%
Grabarczyk et al, 2018	1340	3079		0.4352	[0.4176; 0.4529]	0.4%
Fukuda et al, 2007	168	3185		0.0527	[0.0452; 0.0611]	0.4%
Fogeda et al, 2012	25	2305		0.0108	[0.0070; 0.0160]	0.4%
Fischer et al, 2014	163	1203		0.1355	[0.1166; 0.1561]	0.4%
Feng et al, 2018	1273	1912		0.6658	[0.6441; 0.6869]	0.4%
Fearon et al, 2017	241	4102		0.0588	[0.0517; 0.0664]	0.4%
Harvala et al, 2018	42	480		0.0875	[0.0638; 0.1164]	0.3%
Cleland et al, 2013	73	1559		0.0468	[0.0369; 0.0585]	0.4%
Cangin et al, 2018	377	7656		0.0492	[0.0445; 0.0543]	0.4%
Ditah et al, 2014	490	8814		0.0556	[0.0509; 0.0606]	0.4%
Cai et al, 2016	1842	3337		0.5520	[0.5349; 0.5690]	0.4%
Chiu et al, 2013	129	450		0.2867	[0.2453; 0.3309]	0.3%
Dimeglio et al, 2018	23	300		0.0767	[0.0492; 0.1128]	0.3%
Chan et al, 2017	492	1539		0.3197	[0.2964; 0.3436]	0.4%
Amarapurkar et al, 2008	416	1163		0.3577	[0.3301; 0.3860]	0.4%
Anita et al, 2014	22	148		0.1486	[0.0956; 0.2164]	0.3%
Hardtke et al, 2018	91	408		0.2230	[0.1836; 0.2666]	0.3%
Ataei et al, 2007	31	816		0.0380	[0.0260; 0.0535]	0.3%
Hesamizadeh et al, 2015	45	514		0.0875	[0.0646; 0.1154]	0.3%
Hogema et al, 2016	11	45		0.2444	[0.1288; 0.3954]	0.3%
Hickey et al, 2016	16	198		0.0808	[0.0469; 0.1279]	0.3%
Houcine et al, 2012	37	687		0.0539	[0.0382; 0.0735]	0.3%
Jahromi et al, 2013	26	477		0.0545	[0.0359; 0.0788]	0.3%
Sepanlou et al, 2010	105	1423		0.0738	[0.0607; 0.0886]	0.4%
Adesina et al, 2009	25	186		0.1344	[0.0889; 0.1920]	0.3%
Ricco et al, 2016	9	199		0.0452	[0.0209; 0.0841]	0.3%
Puttini et al, 2015	12	132		0.0909	[0.0479; 0.1534]	0.3%
Zuin et al, 2016	380	3546		0.1072	[0.0972; 0.1178]	0.4%
Scottto et al, 2012	2	151		0.0132	[0.0016; 0.0470]	0.3%
Raooofi et al, 2012	31	400		0.0775	[0.0533; 0.1082]	0.3%
Rahman et al, 2014	90	300		0.3000	[0.2487; 0.3553]	0.3%
Sabato et al, 2017	4	253		0.0158	[0.0043; 0.0400]	0.3%
Chen et al, 2012	2793	14208		0.1966	[0.1901; 0.2032]	0.4%
Madden et al, 2016	324	1161		0.2791	[0.2534; 0.3058]	0.4%
Love et al, 2018	6	291		0.0206	[0.0076; 0.0443]	0.3%
Lopes et al, 2017	78	300		0.2600	[0.2113; 0.3135]	0.3%
Mansuy et al, 2016	2371	10569		0.2243	[0.2164; 0.2324]	0.4%
Lucarelli et al, 2016	153	313		0.4888	[0.4322; 0.5457]	0.3%
Lange et al, 2016	177	1263		0.1401	[0.1215; 0.1605]	0.4%
Kotwal et al, 2014	712	4175		0.1705	[0.1592; 0.1823]	0.4%
Liang et al, 2014	129	307		0.4202	[0.3644; 0.4776]	0.3%
Marcantonio et al, 2018	10	198		0.0505	[0.0245; 0.0909]	0.3%
Lanini et al, 2015	60	1116		0.0538	[0.0413; 0.0687]	0.4%
Johargy et al, 2013	168	900		0.1867	[0.1617; 0.2137]	0.3%
Jia et al, 2014	3721	15862		0.2346	[0.2280; 0.2413]	0.4%
Ma et al, 2010	407	2090		0.1947	[0.1780; 0.2124]	0.4%
Kaufmann et al, 2011	27	550		0.0491	[0.0326; 0.0706]	0.3%
Mansuy et al, 2015	1310	3353		0.3907	[0.3741; 0.4074]	0.4%
Izopet et al, 2015	1083	2538		0.4267	[0.4074; 0.4462]	0.4%
Li et al, 2011	69	173		0.3988	[0.3253; 0.4759]	0.3%
Li et al, 2014	197	1638		0.1203	[0.1049; 0.1370]	0.4%
Juhl et al, 2017	70	449		0.1559	[0.1236; 0.1928]	0.3%
Katiyar et al, 2018	383	633		0.6051	[0.5658; 0.6434]	0.3%
Intharasongkroh et al, 2019	0	1019		0.0000	[0.0000; 0.0036]	0.3%
Juhl et al, 2014	69	1019		0.0677	[0.0531; 0.0849]	0.3%
Nagler et al, 2014	143	997		0.1434	[0.1222; 0.1667]	0.3%
Liu et al, 2019	3419	10256		0.3334	[0.3242; 0.3426]	0.4%
Mahrt et al, 2018	679	3000		0.2263	[0.2115; 0.2417]	0.4%
Kuniholm et al, 2009	3916	18695		0.2095	[0.2037; 0.2154]	0.4%
Krumbholz et al, 2011	18	116		0.1552	[0.0946; 0.2341]	0.3%
Khounvisith et al, 2018	38	210		0.1810	[0.1313; 0.2398]	0.3%





Figure S13. Forest plot of estimated pooled anti-HEV IgG seroprevalence among swine-related occupational population based on different countries.

Note: country named multiple means people in the study are from more than one country.









Figure S14. Forest plot of estimated pooled anti-HEV IgG seroprevalence among special population.





Random effects model 37021
 Heterogeneity: $I^2 = 98\%$, $\tau^2 = 0.0448$, $p = 0$
 Residual heterogeneity: $I^2 = 98\%$, $p = 0$ 0.1543 [0.1282; 0.1824] 100.0%

Figure S15. Forest plot of estimated pooled anti-HEV IgM seroprevalence among special population.




Figure S16. Forest plot of estimated pooled HEV RNA positive rate among special population.




Figure S17. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among hepatitis population.




Figure S18. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among hepatitis population.




Figure S19. Forest plot of estimated pooled HEV RNA positive rate among hepatitis population.






Figure S20. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among HIV population based on different countries.









Figure S21. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among HIV population based on different countries.






Figure S22. Forest plot of estimated pooled HEV RNA positive rate among HIV population based on different countries.




Figure S23. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among transplant population based on different countries.




Figure S24. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among transplant population based on different countries.




Figure S25. Forest plot of estimated pooled HEV RNA positive rate among transplant population based on different countries.




Figure S26. Forest plot of estimated pooled seroprevalence of anti-HEV IgG among hemodialysis population based on different countries.




Figure S27. Forest plot of estimated pooled seroprevalence of anti-HEV IgM among hemodialysis population based on different countries.




Figure S28. Pooled Odd Ratios of anti-HEV IgG seroprevalence to investigate the risk factors for HEV infection among general population.




Figure S29. Odds ratio analysis of anti-HEV seroprevalence for people contacting dogs or not in general population.




Figure S30. Odds ratio analysis of anti-HEV IgG seroprevalence for people contacting cats or not in general population.




Figure S31. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without blood transfusion in general population.




Figure S32. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without consumption of raw meat in general population.



Figure S33. Odds ratio analysis of anti-HEV IgG seroprevalence for people frequently exposed to soil or unexposed to soil in general population.




Figure S34. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without travelling to endemic areas in general population.




Figure S35. Odds ratio analysis of anti-HEV IgG seroprevalence for urban residents or rural residents in general population.




Figure S36. Odds ratio analysis of anti-HEV IgG seroprevalence for people receiving water source of tap or none tap in general population.




Figure S37. Odds ratio analysis of anti-HEV IgG seroprevalence for people accepting education of elementary or above elementary in general population.




Figure S38. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without MSM experience in general population.




Figure S39. Odds ratio analysis of anti-HEV IgG seroprevalence for people with or without IDU experience in general population.







Figure S40. Forest plot of estimated pooled anti-HEV IgG seroprevalence among general population based on different ELISA manufactures.


Note: Those own in-house assays and uncommon commercial kits are classified as ‘Others’







Company = Wantai



Random effects model

Heterogeneity: $I^2 = 100\%$, $\tau^2 = 0.0769$, $p = 0$

Residual heterogeneity: $I^2 = 100\%$, $p = 0$

Figure S41. Funnel plot for anti-HEV IgG seroprevalence among general population.




Figure S42. Egger plot for anti-HEV IgG seroprevalence among general population.




Table S1. Score of studies evaluated by JBI Critical Appraisal Tools.

1. Was the sample frame appropriate to address the target population?
2. Were study participants sampled in an appropriate way?
3. Was the sample size adequate?
4. Were the study subjects and the setting described in detail?
5. Was the data analysis conducted with sufficient coverage of the identified sample?
6. Were valid methods used for the identification of the condition?
7. Was the condition measured in a standard, reliable way for all participants?
8. Was there appropriate statistical analysis?
9. Was the response rate adequate, and if not, was the low response rate managed appropriately?

Study	1	2	3	4	5	6	7	8	9	Score
Legrand-Abravanel et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Haagsma et al,2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Hoerning et al,2012	✓	?	✓	?	✓	✓	?	✓	✓	6
Pischke et al,2010	✓	✓	✓	?	✓	✓	✓	✓	✓	8
Halac et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Rostamzadeh et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Pischke et al, 2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Scotto et al,2015	✓	?	✓	✓	✓	✓	?	✓	✓	7
Pisano et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	7
Nanmoku et al,2019	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Unzueta et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Naik et al,2013	✓	?	✓	-	✓	✓	?	✓	✓	6
Moal et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Koning et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Inagaki et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Mallet et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
de Oliveira et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Buffaz et al, 2014	✓	?	✓	✓	✓	✓	?	✓	✓	7
Abravanel et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Pas et al,2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Riezebos-Brilman et al,2013	✓	✓	✓	-	✓	✓	?	✓	✓	7
Passos et al,2013	✓	?	✓	✓	✓	✓	?	✓	✓	7
Ankorn et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kamar et al,2008	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Moal et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lim et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Buti et al,2010	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Laverdure et al, 2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Magnusson et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lee et al,2005	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Psichogiou et al,1996	✓	✓	✓	-	✓	✓	✓	✓	✓	8
Dalekos et al,1998	✓	?	✓	×	✓	✓	✓	✓	✓	7
Abdel et al,1998	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Harrison et al,2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ding et al,2003	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Mitsui et al,2006	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ben-Ayed et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ricco et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Chen et al,2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Knodler et al,1994	✓	✓	✓	-	✓	✓	?	✓	✓	7
Buti et al,1995	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Cengiz et al,1996	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Parana et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8

Arinsoy et al,1998	✓	?	✓	-	✓	✓	?	✓	✓	7
Mateos et al,1999	✓	?	✓	✓	✓	✓	?	✓	✓	7
Trinta et al,2001	✓	✓	✓	×	✓	✓	?	✓	✓	7
Alavian et al, 2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Halfon et al,1994	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kikuchi et al, 2006	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Sylvan et al,1998	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Taremi et al,2005	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Zekavat et al,2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ayoola et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Javani et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Fabrizi et al,1997	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Irshad et al,2002	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Gessoni et al,1998	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Stefanidis et al,2004	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mobaien et al,2013	✓	✓	✓	×	✓	✓	?	✓	✓	7
Yong et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Maylin et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Politou et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kenfak-Foguena et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Keane et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ng et al,2000	✓	?	✓	✓	✓	✓	?	✓	✓	7
Feldt et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ethakovic et al,2014	✓	✓	✓	-	✓	✓	?	✓	✓	7
Renou et al, 2010	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mateos-Lindemann et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Caron et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Riveiro-Barciela et al,2014	✓	?	✓	✓	✓	✓	?	✓	✓	7
Sellier et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Hassing et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Nouhin et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Crum-Cianflone et al,2012	✓	✓	✓	-	✓	✓	✓	✓	✓	8
Fainboim et al,1999	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Zeng et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Shrestha et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Kaba et al,2011	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Rivero-Juarez et al, 2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Scotto et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Joulaei et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Pineda et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Sherman et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Vazquez-Moron et al,2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Jardi et al,2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Shimizu et al, 2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9

Zhou et al,2018	✓	×	✓	✓	✓	✓	?	✓	✓	7
Rivero-Juarez et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ramezani et al,2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Pischke et al,2010	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Balayan et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Boon et al,2018	✓	?	✓	✓	✓	✓	?	✓	✓	7
Ferreira et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Harritshoj et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bura et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Abravanel et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bezerra et al,2019	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Madejon et al, 2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Salvio et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Pischke et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Kuniholm et al,2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Demi et al,2018	✓	✓	×	✓	✓	✓	✓	✓	✓	8
Enayatollah et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Oladipo et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Kantala et al, 2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Khuroo et al,1994	✓	?	✓	✓	✓	✓	?	✓	✓	7
Yang et al, 2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Pischke et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Psichogiou et al,1995	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Siripanyaphinyo et al,2014	✓	×	✓	✓	✓	✓	?	✓	✓	7
Schulz et al,2016	✓	✓	✓	×	✓	✓	?	✓	✓	7
Ramalingam et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Divizia et al,1999	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Al-Knawy et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Cacciola et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bayram et al,2007	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Chandra et al, 2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Freitas et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Goumba et al,2011	✓	?	✓	×	✓	✓	✓	✓	✓	7
Gupta et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Hyams et al,1996	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Coursaget et al,1998	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Shrestha et al,2003	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mohammad et al,2007	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Guilherme et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Perez-Gracia et al, 2004	✓	✓	✓	✓	✓	✓	?	✓	✓	8
J.-F. TSAI et al,1994	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Tsatsralt-Od et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Chandra et al, 2012	✓	✓	✓	×	✓	✓	✓	✓	✓	8
Fridmana et al,2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9

Albetkova et al,2007	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Koot et al,2015	✓	?	✓	✓	✓	✓	?	✓	✓	7
Kumar et al,2007	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Joon et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kantala et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kang et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Meadar et al,2010	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Engle et al, 2002	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Meng et al,2002	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Zheng et al,2006	✓	✓	✓	?	✓	✓	?	✓	✓	7
Hinjoy et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Utsumi et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Silva et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Traore et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ivanova et al,2015	✓	?	✓	×	✓	✓	✓	✓	✓	7
Caruso et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Masia et al, 2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mughini-Gras et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Vivek et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lee et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
De Sabato et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Zhang et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Yu et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Chaussade et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Widasari 2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Drobeniuc et al,2001	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bouwknegt et al,2008	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Galiana et al,2008	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Olsen et al,2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Withers et al,2002	✓	✓	✓	?	✓	✓	?	✓	✓	7
Lucarelli et al, 2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Verhoef et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lafeber et al, 2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Love et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Lange et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Liang et al, 2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Krumbholz et al,2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Tritz et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Krumbholz et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Tabibi et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Alvarado-Esquivel et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Cong et al,2014	✓	?	✓	×	✓	✓	?	✓	✓	6
Abebe et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8

Rey et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Martinez et al, 2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Munne et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Moaven et al,1995	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lagler et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Fischer et al, 2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Rahman et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Labrique et al,2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Sheikh et al, 2002	✓	✓	✓	✓	✓	✓	?	✓	✓	8
De Paschale et al, 2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Dell'Amico et al,2011	✓	?	✓	✓	✓	✓	?	✓	✓	7
Konomi et al,1999	✓	✓	✓	×	✓	✓	?	✓	✓	7
Gandolfo et al,2003	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bartoloni et al,1999	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Leon et al, 1999	✓	✓	✓	✓	✓	✓	?	✓	✓	8
de Paula et al,2001	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Passos-Castilho et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Goncales et al,2000	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Vitral et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Santos et al,2002	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Hardtke et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Martins et al,2014	✓	✓	✓	?	✓	✓	?	✓	✓	7
Bortoliero et al,2006	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Pavel et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Traore et al,2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Aubry et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Fearon et al, 2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Nouhin et al,2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Nouhin et al,2018	✓	✓	✓	?	✓	✓	✓	✓	✓	8
Yamada et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Wong et al,2004	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Zhuang et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	9
Wang et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	9
Chiu et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	9
Chang et al,2009	✓	?	✓	✓	✓	✓	?	✓	✓	7
Chen et al,2019	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Guo et al,2010	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Yang et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Peng et al,1995	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Jia et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Li et al,2011	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Li et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lee et al,1994	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Liu et al,2019	✓	✓	✓	✓	✓	✓	?	✓	✓	8

Cui et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Zeng et al, 2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Cheng et al,2007	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Meng et al,2015	✓	✓	✓	-	✓	✓	?	✓	✓	7
Toole et al,2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Dong et al,2007	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Geng et al,2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Zhu et al,2008	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Zhu et al, 2014	✓	✓	✓	-	✓	✓	✓	✓	✓	8
Ren et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Cai et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Feng et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Chan et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Chen et al,2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ma et al,2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Li et al,2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lu et al, 2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Li et al,2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Zhilian et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Huang et al, 2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ibarra et al,1994	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Strakova et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Quintana et al,2005	✓	✓	✓	-	✓	✓	?	✓	✓	7
Villalba et al,2010	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lemos et al,2000	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Christensen et al,2008	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Langer et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Dimeglio et al, 2018	✓	?	✓	-	✓	✓	?	✓	✓	6
Boutrouille et al,2007	✓	?	✓	✓	✓	✓	?	✓	✓	7
Mansuy et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mansuy et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Kaba et al,2010	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Takahashi et al,2004	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Takeda et al,2010	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Sakata et al,2008	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Toyoda et al,2008	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Mitsui et al,2005	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Goto et al,2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Fukuda et al, 2007	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Gambel et al,1998	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kamel et al,1995	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Aboulata et al, 2005	✓	✓	✓	?	✓	✓	?	✓	✓	7
Hasan et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Fix et al,2000	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Stoszek et al,2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Gad et al, 2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8

Wenzel et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Juhl et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Mahrt et al,2018	✓	?	✓	✓	✓	✓	✓	✓	✓	8
Jablonka et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Schielke et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Dremsek et al, 2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Meldal et al,2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Adjei et al,2009	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Talarmin et al,1997	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Tripathy et al,2019	✓	✓	✓	?	✓	✓	✓	✓	✓	8
Vivek et al,2010	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Kotwal et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Katiyar et al, 2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Pathak et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Mathur et al,2001	✓	?	✓	✓	✓	✓	✓	✓	✓	8
Achwan et al,2007	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ehteram et al,2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Farshadpour et al,2015	✓	✓	✓	×	✓	✓	✓	✓	✓	8
Assarehzadegan et al,2008	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mohebbi et al,2012	✓	?	✓	✓	✓	✓	?	✓	✓	7
Sotoodeh et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ataei et al, 2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Hesamizadeh et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Sepanlou et al,2010	✓	?	✓	✓	✓	✓	?	✓	✓	7
Raoofi et al, 2012	✓	?	✓	✓	✓	✓	?	✓	✓	7
Jahanbakhsh et al,2017	✓	?	✓	✓	×	✓	?	✓	✓	6
Saffar et al,2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Hickey et al,2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
O'Riordan et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Karenyi et al, 1995	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lachish et al, 2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mor et al, 2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Spada et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Gessoni et al, 1996	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Puttini et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Pavia et al,1998	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Zuin et al, 2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Scotto et al, 2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Marcantonio et al,2019	✓	✓	✓	✓	?	✓	✓	✓	✓	8
Lanini et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Rapicetta et al,1999	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Alecci et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Obaidat et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Cainelli et al, 2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ahn et al,2005	✓	✓	✓	✓	✓	✓	?	✓	✓	8

Yoon et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Yun et al, 2011	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Chironna et al,2001	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Khounvisith et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Alvarez-Munoz et al,1999	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Baptista-Gonzalez et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Alvarado-Esquivel et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Davaalkham et al,2009	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Tsatsralt-Od et al,2007	✓	✓	✓	-	✓	✓	✓	✓	✓	9
Terzic et al, 2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Taha et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Halliday et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Abe et al, 2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Baylis et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Minuk et al, 2007	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Izopet et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Schreuder et al, 2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Clayson et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Shrestha et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mooij et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Slot et al, 2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Sadik et al,2016	✓	✓	✓	×	✓	✓	✓	✓	✓	8
Hogema et al,2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Alberts et al, 2018	✓	?	✓	✓	✓	✓	✓	✓	✓	8
Hewitt et al,2018	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ekanem et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
O. A Adesina et al,2009	✓	?	✓	✓	✓	✓	?	✓	✓	7
Perez 1996	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Grabarczyk et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Korzeniewski et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Sadkowska-Todys et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bura et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Nascimento et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Teixeira et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Oliveira et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Nasrallah et al, 2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Abe et al,2004	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Anita et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Arif et al,1994	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Johargy et al, 2013	✓	?	✓	✓	✓	✓	?	✓	✓	7
Abdelaal et al,1998	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Petrovic et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8

Chow et al,1997	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Grabow et al, 1994	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Madden et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Lopes et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Azman et al,2017	✓	✓	✓	-	✓	✓	?	✓	✓	7
Fogeda et al,2012	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bernal 1995	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Mateos et al,1998	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Buti et al,2013 2008	✓	✓	✓	?	✓	✓	?	✓	✓	7
Buti et al,2006	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Sauleda et al, 2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Kaufmann et al,2011	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Lavanchy et al,1994	✓	✓	✓	-	✓	✓	✓	✓	✓	8
Jeggli et al,2004	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Niederhauser et al,2018	✓	?	✓	✓	✓	✓	✓	✓	✓	8
Poovorawan et al,1996	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Intharasonkroh et al,2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Pilakasiri et al,2009	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Mohanavalli et al,2003	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Houcine et al,2012	✓	?	✓	✓	✓	✓	?	✓	✓	7
Colak et al,2002	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Bayhan et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Atabek et al,2004	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kaya et al,2008	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Sencan et al,2004	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Sidal et al,2001	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Dilek et al,2003	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Nural et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Oncu et al,2006	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Cevrioglu et al,2004	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Miller et al,1998	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Cangin et al, 2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Karenyi et al,1999	✓	✓	✓	×	✓	✓	✓	✓	✓	8
Kuniholm et al,2009	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Eick et al,2010	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Ditah et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Zhang et al,2015	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Kyvernitakis 2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Xu et al,2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Stramer et al,2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Teshale et al, 2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Cleland et al, 2013	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Thom et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Dalton et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Harvala et al,2019	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Ijaz et al,2009	✓	✓	✓	✓	✓	✓	?	✓	✓	8

Pujol et al,1994	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Corwin et al,1996	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Hau et al,1999	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Bawazir et al, 2010	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Maitrey et al,2014	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Gupta et al,2015	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Sadaf et al,2015	✓	✓	✓	?	-	✓	?	✓	✓	6
Ifeorah et al, 2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Adeola et al,2018	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Kumar et al,2001	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Hoad et al,2017	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Harritshoj et al, 2016	✓	✓	✓	✓	✓	✓	?	✓	✓	8
Vollmer et al,2012	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Arankalle et al,2002	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
La Fauci et al,2017	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Minagi et al,2016	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Riezebos-Brilman et al,2013	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Rivero-Juarez et al,2019	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Hewitt et al,2014	✓	✓	✓	✓	✓	✓	✓	✓	✓	9
Meaning of symbol	✓ Yes		× No			? Not clear		-Not applicable		

Table S2. Distribution of HEV genotypes 1-4 in different countries.

Name	Country	HEV-1	HEV-2	HEV-3	HEV-4	Subgroup
Fischer et al, 2015	Austria			7		General population
Dell'Amico et al, 2011	Bolivia			4		General population
Passos et al, 2013	Brazil			3		Transplant
Nouhin et al, 2016	Cambodia			1		General population
Yamada et al, 2015	Cambodia			1	1	General population
Halac et al, 2012	Canada			5		Transplant
Zhu et al, 2008	China				15	General population
Ren et al, 2014	China				3	General population
Ma et al, 2010	China				23	General population
Li et al, 2006	China	1			23	General population
Li et al, 2019	China				1	General population
Rui et al, 2018	China				4	General population
Yu et al, 2009	China				30	General population
Chen et al, 2019	China				4	General population
Yang et al, 2014	China				12	General population
Li et al, 2011	China				1	General population
Li et al, 2014	China				10	General population
Dong et al, 2007	China				25	General population
Zhu et al, 2014	China	5			72	General population
Zheng et al, 2006	China	4		27		Occupational
Vallalba et al, 2012	Cuba			3		Occupational
Harritshoj et al, 2016	Denmark			2		General population
Kantala et al, 2009	Finland	5				Hepatitis
Mansuy et al, 2004	France			16		General population
Kaba et al, 2010	France			1		General population
Kaba et al, 2011	France			1		HIV
Moal et al, 2012	France			17		Transplant
Dremsek et al, 2012	Germany			4		Occupational population
Schielke et al, 2015	Germany			1		Occupational population
Hoerning et al, 2012	Germany			3		Transplant
Pischke et al, 2010	Germany			3		Transplant
Voller et al, 2012	Germany			13		General population
Tripathy et al, 2019	India	2				General population
Pathak et al, 2017	India	22				General population
Persa et al, 2016	Iran	7				General population
O'Riordan et al, 2016	Ireland			3		General population
Lucarelli et al, 2016	Italy			3		General population
Marcantonio et al, 2019	Italy			1		General population
Inagaki et al, 2015	Japan			2		Transplant
Fukuda et al, 2007	Japan			8	3	General population
Sakata et al, 2008	Japan			19	4	General population
Takahashi et al, 2010	Japan			3		General population
Minagi et al, 2016	Japan			36		General population
Ahn et al, 2005	Korea			14		General population
Tsatsralt et al, 2016	Mongolia				12	Hepatitis
Abe et al, 2006	Nepal	3				General population
Shrestha et al, 2003	Nepal	48				Hepatitis
Slot et al, 2013	Netherlands			16		General population
Hogema et al, 2016	Netherlands			17		General population
Suzan et al, 2012	Netherlands			11		Transplant
Brilman et al, 2012	Netherlands			10		Transplant
Koot et al, 2015	Netherlands	4		50		Hepatitis
Grabarczyk et al, 2018	Poland			3		General population

Anita et al, 2014	Romania		6	General population
Sauleda et al, 2014	Spain		3	General population
Jardi et al, 2012	Spain		3	HIV
Foguena et al, 2011	Switzerland		1	HIV
Intharasongkroh et al, 2018	Thailand		3	General population
Siripanyaphinyo et al, 2014	Thailand		5	Hepatitis
Albetkova et al, 2007	Turkmenistan	25		Hepatitis
Harvala et al, 2018	UK		479	General population
Hewitt et al, 2014	UK		79	General population
Cleland et al, 2013	UK		1	General population
Thom et al, 2018	UK		10	General population
Ramalingam et al, 2013	UK		7	Hepatitis
Mark et al, 2015	USA		3	HIV

Table S3. Sensitivity analysis in seroepidemiology of anti-HEV IgG in general population

Study	Prevalence	Lower	Upper
Chang et al, 2009	0.1242	0.1037	0.1464
Geng et al, 2011	0.1242	0.1037	0.1464
Yuan et al, 2017	0.1242	0.1036	0.1463
Maria et al, 2006	0.1247	0.1041	0.1468
Chen et al, 2019	0.1242	0.1037	0.1464
Edward et al, 1997	0.1229	0.1025	0.1449
Corwin et al, 1996	0.1244	0.1039	0.1466
Hassan et al, 2013	0.1244	0.1039	0.1465
Fatemeh et al, 2014	0.1236	0.1031	0.1456
Guo et al, 2009	0.1239	0.1030	0.1464
Halliday et al, 2014	0.1245	0.1039	0.1467
Ahn et al, 2005	0.1244	0.1039	0.1466
Azarkar et al, 2017	0.1241	0.1036	0.1462
Boutrouille et al, 2007	0.1249	0.1043	0.1471
Cainelli et al, 2018	0.1248	0.1042	0.1469
Christensen et al, 2018	0.1239	0.1034	0.1460
Abe et al, 2006	0.1239	0.1033	0.1460
Baylis et al, 2012	0.1254	0.1096	0.1420
Assarehzadegan et al, 2007	0.1245	0.1039	0.1466
Dell'Amico et al, 2011	0.1246	0.1040	0.1467
Yoon et al, 2014	0.1247	0.1042	0.1469
Takahashi et al, 2004	0.1245	0.1040	0.1467
Takahashi et al, 2010	0.1248	0.1041	0.1471
O'Riordan et al, 2016	0.1248	0.1042	0.1469
Spada et al, 2018	0.1246	0.1040	0.1469
Nasrallah et al, 2017	0.1242	0.1036	0.1464
Moaven et al, 1995	0.1249	0.1043	0.1471
Zhuang et al, 2014	0.1241	0.1036	0.1463
Nascimento et al, 2016	0.1243	0.1038	0.1465
Takeda et al, 2010	0.1249	0.1043	0.1471
Minuk et al, 2007	0.1249	0.1043	0.1471
Nouhin et al, 2016	0.1240	0.1035	0.1461
Verhoef et al, 2011	0.1250	0.1044	0.1472
Castilho et al, 2017	0.1246	0.1040	0.1467
Mooij et al, 2018	0.1239	0.1034	0.1461
Lafeber et al, 2017	0.1240	0.1035	0.1462
Yun et al, 2011	0.1246	0.1040	0.1467
Olcay et al, 2003	0.1247	0.1041	0.1469
Rapicetta et al, 1999	0.1250	0.1044	0.1472
Nouhin et al, 2018	0.1237	0.1032	0.1458
Slot et al, 2013	0.1240	0.1035	0.1462
Straková et al, 2016	0.1248	0.1042	0.1469
Wong et al, 2004	0.1243	0.1037	0.1464
Meldal et al, 2013	0.1248	0.1042	0.1470
Wenzel et al, 2014	0.1237	0.1032	0.1457
Petrovi et al, 2014	0.1244	0.1038	0.1465
Wang et al, 2017	0.1240	0.1034	0.1462
Tripathy et al, 2018	0.1243	0.1037	0.1465
Quintana et al, 2005	0.1248	0.1042	0.1469
Taremi et al, 2007	0.1247	0.1041	0.1468
Castilho et al, 2016	0.1246	0.1040	0.1467
Vivek et al, 2010	0.1244	0.1038	0.1466
Zhu et al, 2008	0.1240	0.1035	0.1462
Sakata et al, 2008	0.1249	0.1043	0.1471
Sadik et al, 2016	0.1238	0.1033	0.1458
Mohebbi et al, 2012	0.1246	0.1040	0.1467
Yang et al, 2014	0.1241	0.1036	0.1463
Zhu et al, 2014	0.1238	0.1052	0.1436
Thom et al, 2017	0.1248	0.1042	0.1470
Mor et al, 2015	0.1245	0.1040	0.1467
Villalba et al, 2014	0.1246	0.1040	0.1467
Toyoda et al, 2008	0.1246	0.1040	0.1467
Shrestha et al, 2016	0.1237	0.1032	0.1458
Mohammad et al, 2017	0.1239	0.1034	0.1460
Yamada et al, 2015	0.1243	0.1037	0.1464
Vitral et al, 2014	0.1245	0.1039	0.1466
Peng et al, 1995	0.1247	0.1041	0.1468
Talarmin et al, 1997	0.1247	0.1041	0.1469
Sauleda et al, 2014	0.1242	0.1036	0.1465
Ren et al, 2013	0.1240	0.1034	0.1463
Santos et al, 2002	0.1249	0.1044	0.1471
Miller et al, 1998	0.1252	0.1046	0.1474
Parsa et al, 2016	0.1247	0.1041	0.1468

Pittaras et al, 2014	0.1246	0.1040	0.1467
Schreuder et al, 2016	0.1248	0.1042	0.1470
Jahromi et al, 2013	0.1248	0.1042	0.1469
Niederhauser et al, 2017	0.1242	0.1036	0.1464
Teoharov et al, 2014	0.1246	0.1040	0.1467
Bortoliero et al, 2006	0.1250	0.1044	0.1471
Hewitt et al, 2018	0.1246	0.1040	0.1467
Alberts et al, 2018	0.1249	0.1043	0.1471
Grabarczyk et al, 2018	0.1236	0.1031	0.1457
Gessoni et al, 1996	0.1249	0.1043	0.1471
Fukuda et al, 2007	0.1248	0.1042	0.1469
Fogeda et al, 2012	0.1251	0.1045	0.1472
Fischer et al, 2014	0.1244	0.1039	0.1466
Feng et al, 2018	0.1231	0.1027	0.1451
Fearon et al, 2017	0.1247	0.1041	0.1469
Harvala et al, 2018	0.1246	0.1040	0.1468
Cleland et al, 2013	0.1248	0.1042	0.1470
Cangin et al, 2018	0.1248	0.1042	0.1470
Ditah et al, 2014	0.1248	0.1041	0.1470
Paula et al, 2001	0.1248	0.1043	0.1470
Goncales et al, 2000	0.1248	0.1042	0.1469
Cai et al, 2016	0.1234	0.1029	0.1454
Chiu et al, 2013	0.1240	0.1035	0.1461
Dimeglio et al, 2018	0.1247	0.1041	0.1468
Ding et al, 2003	0.1249	0.1043	0.1471
Chan et al, 2017	0.1239	0.1034	0.1460
Arif et al, 1994	0.1245	0.1039	0.1467
Abdelaal et al, 1995	0.1243	0.1038	0.1465
Amarapurkar et al, 2008	0.1238	0.1033	0.1459
Anita et al, 2014	0.1244	0.1038	0.1465
Grabow et al, 1994	0.1250	0.1044	0.1471
Hardtke et al, 2018	0.1242	0.1036	0.1463
Ataei et al, 2007	0.1249	0.1043	0.1470
Hesamizadeh et al, 2015	0.1246	0.1040	0.1468
Hogema et al, 2016	0.1241	0.1036	0.1462
Hickey et al, 2016	0.1246	0.1041	0.1468
Houcine et al, 2012	0.1248	0.1042	0.1469
Jahromi et al, 2013	0.1248	0.1042	0.1469
Sepanlou et al, 2010	0.1247	0.1041	0.1468
Mitsui et al, 2005	0.1250	0.1044	0.1471
Adesina et al, 2009	0.1244	0.1039	0.1466
Bernal et al, 1995	0.1250	0.1044	0.1471
Pujol et al, 1994	0.1249	0.1043	0.1470
Ricco et al, 2016	0.1248	0.1042	0.1470
Puttini et al, 2015	0.1246	0.1040	0.1467
Pavia et al, 1998	0.1251	0.1045	0.1473
Zuin et al, 2016	0.1245	0.1039	0.1467
Scotto et al, 2012	0.1250	0.1044	0.1472
Raooft et al, 2012	0.1247	0.1041	0.1468
Rahman et al, 2014	0.1240	0.1034	0.1461
Poovorawan et al, 1996	0.1247	0.1042	0.1469
Sabato et al, 2017	0.1250	0.1044	0.1472
Chen et al, 2012	0.1242	0.1035	0.1466
Madden et al, 2016	0.1240	0.1035	0.1461
Love et al, 2018	0.1250	0.1044	0.1471
Lopes et al, 2017	0.1241	0.1035	0.1462
Mansuy et al, 2016	0.1242	0.1035	0.1464
Karetny et al, 1995	0.1249	0.1043	0.1471
Lucarelli et al, 2016	0.1235	0.1030	0.1456
Lange et al, 2016	0.1244	0.1039	0.1466
Kotwal et al, 2014	0.1243	0.1037	0.1465
Liang et al, 2014	0.1237	0.1032	0.1458
Mateos et al, 1998	0.1249	0.1043	0.1470
Marcantonio et al, 2018	0.1248	0.1042	0.1469
Karetnyi et al, 1999	0.1248	0.1042	0.1469
Lanini et al, 2015	0.1248	0.1042	0.1469
Johargy et al, 2013	0.1243	[0.1037	0.1464
Jia et al, 2014	0.1241	0.1034	0.1465
Ma et al, 2010	0.1243	0.1037	0.1464
Kaufmann et al, 2011	0.1248	0.1042	0.1469
Mansuy et al, 2004	0.1245	0.1040	0.1467
Mansuy et al, 2015	0.1237	0.1032	0.1458
Izopet et al, 2015	0.1237	0.1032	0.1457
Li et al, 2011	0.1237	0.1032	0.1458
Konomi et al, 1999	0.1244	0.1038	0.1465
Li et al, 2014	0.1245	0.1039	0.1466
Juhl et al, 2017	0.1244	0.1038	0.1465
Katiyar et al, 2018	0.1232	0.1028	0.1453
Intharasongkroh et al, 2019	0.1253	0.1047	0.1475

Juhl et al, 2014	0.1247	0.1041	0.1469
Kamel et al, 1995	0.1243	0.1038	0.1465
Nagler et al, 2014	0.1244	0.1038	0.1465
Langer et al, 1997	0.1251	0.1045	0.1473
Lee et al, 1993	0.1248	0.1042	0.1470
Lavanchy et al, 1994	0.1248	0.1042	0.1470
Ibarra et al, 1994	0.1243	0.1038	0.1464
Liu et al, 2019	0.1239	0.1033	0.1461
Mahrt et al, 2018	0.1242	0.1036	0.1463
Kuniholm et al, 2009	0.1242	0.1034	0.1466
Krumbholz et al, 2011	0.1244	0.1038	0.1465
Khounvisith et al, 2018	0.1243	0.1037	0.1464
Krumbholz et al, 2014	0.1245	0.1039	0.1466
Jeggli et al, 2015	0.1249	0.1043	0.1470
Kantala et al, 2015	0.1246	0.1040	0.1467
Kang et al, 2017	0.1242	0.1037	0.1463
Korzeniewski et al, 2018	0.1248	0.1042	0.1469
Li et al, 2006	0.1236	0.1031	0.1457
Labrique et al, 2009	0.1242	0.1036	0.1463
Jablonka et al, 2017	0.1242	0.1037	0.1463
Matins et al, 2014	0.1248	0.1042	0.1469
Jahanbakhsh et al, 2017	0.1241	0.1036	0.1462
Kaba et al, 2010	0.1245	0.1039	0.1466
Chironna et al, 1999	0.1249	0.1043	0.1470
Rapicetta et al, 1999	0.1245	0.1039	0.1466
Azman et al, 2017	0.1229	0.1025	0.1449
Lachish et al, 2013	0.1252	0.1046	0.1473
Esquivel et al, 2014	0.1238	0.1033	0.1459
Cui et al, 2016	0.1242	0.1036	0.1463
Schielke et al, 2015	0.1242	0.1037	0.1463
Nübling et al, 2002	0.1248	0.1043	0.1470
Todys et al, 2015	0.1242	0.1037	0.1464
Meadler et al, 2008	0.1249	0.1044	0.1471
Tabili et al, 2013	0.1242	0.1036	0.1463
Pilakasiri et al, 2009	0.1245	0.1039	0.1466
Ghorbani et al, 2007	0.1251	0.1045	0.1472
Bura et al, 2018	0.1250	0.1044	0.1472
Dremsek et al, 2012	0.1244	0.1038	0.1465
Eick et al, 2010	0.1251	0.1045	0.1472
Gambel et al, 1998	0.1242	0.1037	0.1463
Alecci et al, 1997	0.1251	0.1045	0.1472
Chaussade et al, 2013	0.1241	0.1035	0.1462
Whiters et al, 2002	0.1249	0.1044	0.1471
Zeng et al, 2014	0.1248	0.1042	0.1469
Yu et al, 2009	0.1242	0.1036	0.1464
Teixeira et al, 2017	0.1244	0.1039	0.1466
Widasari et al, 2013	0.1247	0.1042	0.1469
Olsen et al, 2006	0.1246	0.1040	0.1467
Zhang et al, 2017	0.1237	0.1032	0.1458
Bouwknegt et al, 2008	0.1250	0.1044	0.1472
Drobeniuc et al, 2001	0.1241	0.1036	0.1462
Galiana et al, 2008	0.1248	0.1042	0.1470
Dalton et al, 2017	0.1250	0.1044	0.1471
Cheng et al, 2007	0.1244	0.1038	0.1465
Pathak et al, 2018	0.1241	0.1036	0.1462
Sheikh et al, 2002	0.1233	0.1028	0.1453
Chow et al, 1996	0.1244	0.1039	0.1466
Colak et al, 2002	0.1251	0.1045	0.1473
Cong et al, 2014	0.1241	0.1036	0.1463
Terzic et al, 2009	0.1247	0.1042	0.1469
Bayhan et al, 2016	0.1248	0.1042	0.1470
Abe et al, 2004	0.1243	0.1037	0.1464
Aboulata et al, 2005	0.1241	0.1036	0.1462
Achwan et al, 2007	0.1247	0.1042	0.1469
Atabek et al, 2004	0.1247	0.1042	0.1469
Buti et al, 2008	0.1248	0.1042	0.1470
Cevahir et al, 2013	0.1245	0.1039	0.1466
Davaalkham et al, 2009	0.1251	0.1045	0.1473
Ekanem et al, 2015	0.1247	0.1041	0.1468
Gandolfo et al, 2003	0.1251	0.1045	0.1473
Goto et al, 2006	0.1249	0.1043	0.1471
Hasan et al, 2016	0.1241	0.1035	0.1462
Kaya et al, 2007	0.1252	0.1046	0.1473
Krumbholz et al, 2014	0.1251	0.1045	0.1472
Lin et al, 2004	0.1249	0.1043	0.1471
Mathur et al, 2001	0.1241	0.1035	0.1462
Meng et al, 2015	0.1245	0.1039	0.1467
Mohanavalli et al, 2002	0.1246	0.1040	0.1468
Oliveira et al, 2017	0.1251	0.1045	0.1472

Sencan et al, 2003	0.1247	0.1041	0.1468
Shamsizadeh et al, 2009	0.1246	0.1041	0.1468
Sidal et al, 2001	0.1250	0.1044	0.1471
Bira et al, 2007	0.1251	0.1045	0.1473
Hau et al, 1999	0.1249	0.1043	0.1471
Toole et al, 2006	0.1239	0.1034	0.1460
Saffar et al, 2009	0.1250	0.1044	0.1471
Bawazir et al, 2010	0.1245	0.1040	0.1467
Dong et al, 2007	0.1243	0.1036	0.1466
Lu et al, 2009	0.1243	0.1037	0.1465
Fix et al, 2000	0.1237	0.1031	0.1458
Ijaz et al, 2009	0.1244	0.1039	0.1466
Rey et al, 1997	0.1250	0.1044	0.1472
Munoz et al, 1999	0.1245	0.1039	0.1467
Héctor et al, 2017	0.1251	0.1045	0.1473
Li et al, 2019	0.1244	0.1038	0.1465
Lee et al, 2013	0.1250	0.1044	0.1471
Serkan et al, 2005	0.1247	0.1041	0.1468
Christophe et al, 2004	0.1247	0.1041	0.1468
Dorcas et al, 2018	0.1245	0.1039	0.1466
Rui et al, 2018	0.1242	0.1037	0.1463
Maria et al, 2010	0.1249	0.1043	0.1470
Zakieh et al, 2013	0.1249	0.1043	0.1470
Sonia et al, 2006	0.1226	0.1023	0.1444
Niguse et al, 2018	0.1237	0.1032	0.1457
Caron et al, 2008	0.1244	0.1039	0.1466
Caron et al, 2012	0.1247	0.1041	0.1469
Sandro et al, 2017	0.1247	0.1041	0.1468
Cosme et al, 2014	0.1248	0.1042	0.1469
Cevrioglu et al, 2004	0.1245	0.1039	0.1466
Farshadpour et al, 2018	0.1247	0.1041	0.1469
Gad et al, 2011	0.1233	0.1028	0.1454
Adjei et al, 2009	0.1246	0.1040	0.1467
Huang et al, 2013	0.1246	0.1040	0.1467
Paschale et al, 2016	0.1242	0.1036	0.1463
Alizadeh et al, 2016	0.1249	0.1043	0.1471
Abebe et al, 2017	0.1239	0.1034	0.1460
Traore et al, 2012	0.1239	0.1034	0.1460
Aubry et al, 1997	0.1244	0.1039	0.1465
Gambel et al, 1998	0.1245	0.1039	0.1466
Zhang et al, 2015	0.1242	0.1036	0.1464
Kyvermitakis et al, 2015	0.1245	0.1040	0.1467
Tashale et al, 2015	0.1247	0.1040	0.1469
Xu et al, 2013	0.1243	0.1037	0.1464
Stramer et al, 2015	0.1244	0.1039	0.1466
Meng et al, 2001	0.1243	0.1037	0.1464
Esquivel et al, 2015	0.1247	0.1041	0.1468
Esquivel et al, 2015	0.1248	0.1042	0.1469
Perez et al, 1996	0.1248	0.1042	0.1470
Wassaf et al, 2014	0.1248	0.1042	0.1470
Munne et al, 2014	0.1244	0.1038	0.1465
Bartoloni et al, 1999	0.1247	0.1041	0.1468
Leon et al, 1999	0.1242	0.1037	0.1463
Trinta et al, 2001	0.1251	0.1045	0.1473
Lemos et al, 2000	0.1250	0.1044	0.1472

Table S4. Manufactures of ELISA assays used in general population.

Study	year	manufactures
Chang et al	2009	Wantai
Geng et al	2011	wantai
Yuan et al	2017	Wantai
Maria et al	2006	Biokit
Chen et al	2019	Wantai
Edward et al	1997	Diagnostic Biotechnology
Corwin et al	1996	Abbott Laboratories
Hassan et al	2013	Dia.Pro
Fatemeh et al	2014	Dia.Pro
Guo et al	2009	Wantai
Halliday et al	2014	Wantai
Ahn et al	2005	Genelabs Diagnostics
Azarkar et al	2017	Delavara Company
Boutrouille et al	2007	Genelabs Diagnostics
Cainelli et al	2018	Dia.Pro
Christensen et al	2018	Unknown
Abe et al	2006	In-house assay
Baylis et al	2012	Wantai
Assarehzadegan et al	2007	Biokit
Dell'Amico et al	2011	Dia.Pro
Yoon et al	2014	Wantai
Takahashi et al	2004	In-house assay
Takahashi et al	2010	In-house assay
O'Riordan et al	2016	Wantai
Spada et al	2018	Wantai
Nasrallah et al	2017	Wantai
Moaven et al	1995	Genelabs Diagnostics
Zhuang et al	2014	Pierce
Nascimento et al	2016	Mikrogen
Takeda et al	2010	Cosmic corporation
Minuk et al	2007	Genelabs Diagnostics
Nouhin et al	2016	Wantai
Verhoef et al	2011	MP Diagnostics
Castilho et al	2017	Wantai
Mooij et al	2018	Wantai
Lafeber et al	2017	Wantai
Yun et al	2011	Dia.Pro
Olcay et al	2003	Genelabs Diagnostics
Rapicetta et al	1999	Abbott Laboratories
Nouhin et al	2018	Wantai
Slot et al	2013	Wantai
Straková et al	2016	Dia.Pro
Wong et al	2004	GeneLabs Diagnostics
Meldal et al	2013	Wantai
Wenzel et al	2014	Wantai
Petrovi et al	2014	In-house assay
Wang et al	2017	Wantai
Tripathy et al	2018	Genelabs Diagnostic/Wantai
Quintana et al	2005	Unknown
Taremi et al	2007	Dia.Pro
Castilho et al	2016	Wantai
Vivek et al	2010	MP Bio
Zhu et al	2008	Wantai
Sakata et al	2008	Cosmic Corporation
Sadik et al	2016	Wantai
Mohebbi et al	2012	Dia.Pro
Yang et al	2014	Wantai
Zhu et al	2014	Wantai
Thom et al	2017	Wantai
Mor et al	2015	Diagnostic Systems
Villalba et al	2014	Cavendish
Toyoda et al	2008	In-house assay
Shrestha et al	2016	Wantai
Mohammad et al	2017	Fortress Diagnostics
Yamada et al	2015	Institute of Immunology Company
Vitral et al	2014	Mikrogen
Peng et al	1995	Diagnostic Biotechnolgy
Talarmin et al	1997	Abbott Laboratories
Sauleda et al	2014	Wantai
Ren et al	2013	Diagnostic Biotechnology
Santos et al	2002	Abbott Laboratories
Miller et al	1998	Abbott Laboratories

Parsa et al	2016	Dia.Pro
Pittaras et al	2014	Adaltis
Schreuder et al	2016	Wantai
Jahromi et al	2013	Unknown
Niederhauser et al	2017	Wantai
Teoharov et al	2014	Dia.Pro
Bortoliero et al	2006	Abbott Laboratories
Hewitt et al	2018	Wantai
Alberts et al	2018	Wantai
Grabarczyk et al	2018	Wantai
Gessoni et al	1996	Abbott Laboratories
Fukuda et al	2007	Unknown
Fogeda et al	2012	Mikrogen GmbH
Fischer et al	2014	Wantai
Feng et al	2018	Wantai
Fearon et al	2017	Wantai
Harvala et al	2018	Wantai
Cleland et al	2013	Wantai
Cangin et al	2018	Soronno
Ditah et al	2014	Soronno
Paula et al	2001	Organon Teknika
Goncales et al	2000	Abbott Laboratories
Cai et al	2016	Wantai
Chiu et al	2013	Biotech Laboratories
Dimeglio et al	2018	Wantai
Ding et al	2003	In-house assay
Chan et al	2017	Unknown
Arif et al	1994	Abbott Laboratories
Abdelaal et al	1995	Unknown
Amarapurkar et al	2008	Unknown
Anita et al	2014	MP Biomedicals
Grabow et al	1994	Unknown
Hardtke et al	2018	Wantai
Ataei et al	2007	Dia.Pro
Hesamizadeh et al	2015	Dia.Pro
Hogema et al	2016	Wantai
Hickey et al	2016	Wantai
Houcine et al	2012	MP Diagnostics
Jahromi et al	2013	Dia.Pro
Sepanlou et al	2010	Dia.Pro
Mitsui et al	2005	Genelabs Diagnostics
Adesina et al	2009	Dia.Pro
Bernal et al	1995	Abbott Laboratories
Pujol et al	1994	Abbott Laboratories
Ricco et al	2016	Wantai/ Dia.Pro
Puttini et al	2015	Adaltis
Pavia et al	1998	International Immunodiagnosics
Zuin et al	2016	Dia.Pro
Scotto et al	2012	Dia.Pro
Raoofi et al	2012	Unknown
Rahman et al	2014	Institute of Immunology
Poovorawan et al	1996	Genelabs Diagnostics
Sabato et al	2017	Bio-Chain Institute
Chen et al	2012	In-house assay
Madden et al	2016	Wantai
Love et al	2018	Wantai/Dia.Pro
Lopes et al	2017	Fortress Diagnostics
Mansuy et al	2016	Wantai
Karetny et al	1995	Unknown
Lucarelli et al	2016	Wantai
Lange et al	2016	Wantai
Kotwal et al	2014	Unknown
Liang et al	2014	Wantai
Mateos et al	1998	Abbott Laboratories
Marcantonio et al	2018	Wantai
Karetnyi et al	1999	In-house assay
Lanini et al	2015	Dia.Pro
Johargy et al	2013	Bioelisa
Jia et al	2014	MP Diagnostics
Ma et al	2010	Wantai
Kaufmann et al	2011	MP Biomedicals
Mansuy et al	2004	Abbott Laboratories
Mansuy et al	2015	Wantai
Izopet et al	2015	Wantai
Li et al	2011	Wantai
Konomi et al	1999	In-house assay
Li et al	2014	Wantai
Juhl et al	2017	Wantai

Katiyar et al	2018	Wantai
Intharasongkroh et al	2019	Euroimmun/Wantai
Juhl et al	2014	Wantai
Kamel et al	1995	Abbott Laboratories
Nagler et al	2014	Fortress Diagnostics
Langer et al	1997	Abbott Laboratories
Lee et al	1993	Genelabs Diagnostics
Lavanchy et al	1994	Abbott Laboratories
Ibarra et al	1994	Abbott Laboratories
Liu et al	2019	Unknown
Mahrt et al	2018	Wantai
Kuniholm et al	2009	In-house assay
Krumbholz et al	2011	Mikrogen GmbH
Khounvisith et al	2018	Euroimmun
Krumbholz et al	2014	Mikrogen GmbH
Jeggli et al	2015	Abbott Laboratories
Kantala et al	2015	Mikrogen GmbH
Kang et al	2017	Wantai
Korzeniewski et al	2018	Mikrogen
Li et al	2006	Wantai
Labrique et al	2009	In-house assay
Jablonka et al	2017	Wantai
Matins et al	2014	Mikrogen GmbH
Jahanbakhsh et al	2017	Dia.Pro
Kaba et al	2010	Adaltis
Chironna et al	1999	Nuclear Laser Medicine
Rapicetta et al	1999	DSI
Azman et al	2017	Wantai
Lachish et al	2013	Abbott Laboratories
Esquivel et al	2014	Dia.Pro
Cui et al	2016	Wantai
Schielke et al	2015	Mikrogen GmbH
Nübling et al	2002	Unknown
Todys et al	2015	Microgen
Meador et al	2008	MP Biomedical
Tabili et al	2013	Wantai
Pilakasiri et al	2009	In-house assay
Ghorbani et al	2007	Dia.Pro
Bura et al	2018	Euroimmun
Dremsek et al	2012	In-house assay
Eick et al	2010	WRAIR
Gambel et al	1998	Genelabs Diagnostics
Alecci et al	1997	Abbott Laboratories
Chaussade et al	2013	MP Biomedicals
Whiters et al	2002	Genelabs Diagnostics
Zeng et al	2014	Wantai
Yu et al	2009	Wantai
Teixeira et al	2017	Mikrogen
Widasari et al	2013	MP Biomedicals
Olsen et al	2006	Abbott Laboratories
Zhang et al	2017	Wantai
Bouwknegt et al	2008	Abbott/Genelabs Diagnostics
Drobeniuc et al	2001	Unknown
Galiana et al	2008	Mikrogen
Dalton et al	2017	Wantai
Cheng et al	2007	Genelabs Diagnostics
Pathak et al	2018	MP Diagnostics
Sheikh et al	2002	In-house assay
Chow et al	1996	Genelabs Diagnostics
Colak et al	2002	Genelabs Diagnostics
Cong et al	2014	Wantai
Terzic et al	2009	Dia.Pro
Bayhan et al	2016	Dia.Pro
Abe et al	2004	In-house assay
Aboulata et al	2004	Unknown
Achwan et al	2007	In-house assay
Atabek et al	2004	Unknown
Buti et al	2008	Biokit
Cevahir et al	2013	BLK diagnostics
Davaalkham et al	2009	In-house assay
Ekanem et al	2015	Springfield Township
Gandolfo et al	2003	Abbott Laboratories
Goto et al	2006	Cosmic Corporation
Hasan et al	2016	Adaltis/MP Diagnostics
Kaya et al	2007	Genelabs Diagnostic
Krumbholz et al	2014	Mikrogen
Lin et al	2004	Abbott Laboratories
Mathur et al	2001	unknown

Meng et al	2015	Wantai
Mohanavalli et al	2002	Millipore
Oliveira et al	2017	Mikrogen
Sencan et al	2003	Giuliana Diagnostica
Shamsizadeh et al	2009	Biokit
Sidal et al	2001	Unknown
Bira et al	2007	In-house assay
Hau et al	1999	Abbott Laboratories
Toole et al	2006	Wantai
Saffar et al	2009	Dia.Pro
Bawazir et al	2010	MP Diagnostic
Dong et al	2007	In-house assay
Lu et al	2009	Wantai
Fix et al	2000	Abbott Laboratories
Ijaz et al	2009	Fortress Diagnostics
Rey et al	1997	Abbott Laboratories
Munoz et al	1999	Abbott Laboratories
Héctor et al	2017	Euroimmun
		Medizinische
Li et al	2019	Wantai
Lee et al	2013	Wantai
Serkan et al	2005	Global Diagnostics
Christophe et al	2004	Wantai
Dorcas et al	2018	Innovita
Rui et al	2018	Wantai
Maria et al	2010	Dia.Pro
Zakieh et al	2013	Dia.Pro
Sonia et al	2006	NIH in-house EIA
Niguse et al	2018	Wantai
Caron et al	2008	Gebelabs Diagnostic
Caron et al	2012	Gebelabs Diagnostic
Sandro et al	2017	Dia.Pro
Cosme et al	2014	Dia.Pro
Cevrioglu et al	2004	Virotech GmbH
Farshadpour et al	2018	Dia.Pro
Gad et al	2011	Gebelabs Diagnostic
		International
Adjei et al	2009	Immunodiagnosics
		Unknown
Huang et al	2013	Dia.Pro
Paschale et al	2016	Dia.Pro
Alizadeh et al	2016	Dia.Pro
Abebe et al	2017	Wantai
Traore et al	2012	Dia.Pro
Aubry et al	1997	Unknown
Gambel et al	1998	Unknown
Zhang et al	2015	Unknown
Kyvernitakis et al	2015	Mikrogen
Tashale et al	2015	DSI
Xu et al	2013	Wantai
Stramer et al	2015	Unknown
Meng et al	2001	In-house assay
Esquivel et al	2015	Dia.Pro
Esquivel et al	2015	Dia.Pro
Perez et al	1996	Abbott Laboratories
Wassaf et al	2014	Dia.Pro
Munne et al	2014	Dia.Pro
Bartoloni et al	1999	Abbott Laboratories
Leon et al	1999	Abbott Laboratories
Trinta et al	2001	Abbott Laboratories
Lemos et al	2000	Unknown

